V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20213129 | 20088657 | 1.71 | 86.4 | 03 | 2019-03-28 | 2019-03-29 | NEO-AEGIS TRIAL | 02 | N | CYCLOPHOSPHAMIDE + THALIDOMIDE | 101865402 |
| 20213157 | 20088658 | 1.63 | 76 | Adjuvant (A) | 2019-01-12 | 2019-01-12 | Cisplatin + Fluorouracil + RT 5day | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 101165793 |
| 20213158 | 20088659 | 1.55 | 80.9 | Palliative (P) | 2016-03-04 | 2016-03-04 | Fluorouracil + Folinic + RT Bossett | N | N | CARBOPLATIN + DOXORUBICIN + MITOMYCIN | 101325699 |
| 20213191 | 20088660 | 1.58 | 64.5 | Palliative (P) | 2018-06-30 | 2018-07-12 | FOXTROT TRIAL | N | N | IBRUTINIB | 101484197 |
| 20213352 | 20088661 | 1.76 | 81.1 | 03 | 2017-10-14 | 2017-11-27 | OXALIPLATIN + MDG + PANITUMUMAB | 01 | Y | GEMCITABINE + PACLITAXEL | 101180809 |
| 20213370 | 20088662 | 1.73 | 72.3 | 03 | 2017-01-22 | 2017-01-30 | null | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101854536 |
| 20213465 | 20088663 | 1.73 | 60.7 | 03 | 2017-02-28 | 2017-03-12 | ECarboF | N | N | HYDROXYCARBAMIDE | 100019909 |
| 20213469 | 20088664 | 1 | 90.4 | 03 | 2018-10-22 | 2018-10-22 | NEO-AEGIS TRIAL | 02 | N | GEMCITABINE + PACLITAXEL | 100484225 |
| 20213555 | 20088665 | 1.58 | 82 | 03 | 2019-07-26 | 2019-08-11 | FEC + DOCETAXEL | 02 | N | PLATFORM TRIAL | 101622761 |
| 20213584 | 20088666 | 1.67 | 62.8 | 03 | 2022-02-20 | 2022-02-20 | NEO-AEGIS TRIAL | 02 | N | NAB-PACLITAXEL | 100971313 |
| 20213634 | 20088668 | 1.61 | 69.8 | Palliative (P) | 2019-01-26 | 2019-02-15 | FOXTROT TRIAL | 02 | null | EVEROLIMUS | 100412321 |
| 20213643 | 20088669 | 1.68 | null | null | 2015-11-15 | 2015-11-22 | Hydroxycarbamide | 01 | N | CHOP R | 101751744 |
| 20213694 | 20088670 | null | null | 03 | 2018-06-19 | 2018-06-19 | Capecitabine+Cisplatin+Streptozocin | 02 | N | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 100320276 |
| 20213697 | 20088671 | 1.64 | 105 | Palliative (P) | null | 2017-04-06 | Cisplatin + Fluorouracil + RT 5day | 01 | N | MITOMYCIN | 100147694 |
| 20213802 | 20088673 | 1.61 | 55.6 | Palliative (P) | 2020-03-06 | 2020-03-13 | PACLITAXEL | 02 | N | PANTHER TRIAL | 100049754 |
| 20213947 | 20088675 | 1.75 | 75 | 03 | 2018-07-29 | 2018-07-29 | EOF | 02 | N | EVEROLIMUS | 101069901 |
| 20214040 | 20088677 | 1.89 | 66.05 | Palliative (P) | 2016-11-04 | 2016-11-04 | null | 02 | null | EVEROLIMUS | 101284606 |
| 20214103 | 20088678 | 1.75 | 70.9 | Palliative (P) | 2016-11-29 | 2016-12-01 | EEX | 02 | N | NOT MATCHED | 100473129 |
| 20214131 | 20088679 | 1.68 | 45.4 | 03 | 2018-08-17 | 2018-08-24 | PRICKLE trial | 02 | N | SUNITINIB | 101357417 |
| 20214192 | 20088680 | 1.63 | 81.8 | 03 | 2019-03-29 | 2019-03-29 | CARBOPLATIN + DOCETAXEL + Pertuzumab + Trastuzumab | 02 | N | MITOMYCIN | 100271636 |
| 20214213 | 20088681 | 1.57 | 62.6 | null | 2019-09-11 | 2019-09-11 | MPT | 01 | N | PLATO TRIAL | 101392623 |
| 20214227 | 20088682 | 1.6 | 66.9 | Palliative (P) | 2021-01-25 | 2021-01-30 | ARISTOTLE TRIAL | 02 | N | ACELARATE TRIAL | 101716428 |
| 20214374 | 20088684 | null | 65.3 | Adjuvant (A) | 2016-11-10 | 2016-11-10 | null | 02 | Y | CYCLOPHOSPHAMIDE + RITUXIMAB | 100371394 |
| 20214385 | 20088686 | 1.82 | 55.7 | null | 2019-08-29 | 2019-09-25 | ESPAC-4 TRIAL | 02 | N | CARBOPLATIN + FLUOROURACIL + STREPTOZOCIN | 100402622 |
| 20214441 | 20088687 | 1.73 | 73.7 | null | 2019-08-01 | 2019-08-15 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 100263496 |
| 20214544 | 20088688 | 1.8 | 33.8 | null | 2016-10-27 | 2016-11-09 | MITOMYCIN | 01 | N | MITOMYCIN | 101807236 |
| 20214580 | 20088689 | 1.6 | 61.8 | 03 | 2019-10-24 | 2019-10-30 | null | 01 | N | LENALIDOMIDE | 100106812 |
| 20214585 | 20088690 | 1.86 | 103 | 03 | null | 2018-06-13 | NEO-AEGIS TRIAL | 01 | N | CAP + RT | 100678103 |
| 20214697 | 20088691 | null | null | Palliative (P) | 2017-07-27 | 2017-08-05 | COMPARZ trial | 02 | N | MYELOMA XIV TRIAL | 101393969 |
| 20214762 | 20088692 | 1.63 | 55.3 | 03 | 2019-06-11 | 2019-06-16 | TEMOZOLOMIDE | 2 | N | CISPLATIN + TEYSUNO | 100886212 |
| 20214764 | 20088693 | 1.59 | 79.2 | Palliative (P) | 2017-05-27 | 2017-07-03 | Carboplatin + Pemetrexed | N | N | RALTITREXED | 101579208 |
| 20214788 | 20088694 | 1.6 | null | 03 | null | 2019-08-07 | R GCVP | N | N | ARISTOTLE TRIAL | 101481309 |
| 20214799 | 20088695 | 1.66 | 49 | Palliative (P) | 2018-04-06 | 2018-04-13 | Docetaxel 100mg/m2 (21 day) | 01 | N | CAV | 101000117 |
| 20214838 | 20088696 | 1.82 | 66.6 | 03 | 2016-09-16 | 2016-10-21 | OXALIPLATIN + MDG + PANITUMUMAB | N | N | CARBO + FLUOROURACIL | 101152518 |
| 20214855 | 20088698 | 1.68 | 46.9 | Palliative (P) | 2016-03-12 | 2016-03-14 | EC | 1 | N | FOXTROT TRIAL | 100402843 |
| 20214887 | 20088699 | 1.79 | 82.6 | Palliative (P) | 2019-01-22 | 2019-01-22 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | Y | DOCETAXEL | 100602372 |
| 20214912 | 20088700 | 1.76 | 63 | Palliative (P) | null | 2018-10-30 | FCiSt | 01 | N | ESPAC TRIAL | 100294619 |
| 20214936 | 20088701 | 1.54 | 92 | Adjuvant (A) | 2018-09-22 | 2018-09-22 | CAPECITABINE + Cetuximab + OXALIPLATIN | N | Y | ESPAC TRIAL | 101831960 |
| 20215004 | 20088703 | null | 57.85 | Palliative (P) | 2017-01-12 | 2017-02-17 | EEF or EOF | 02 | N | ARISTOTLE TRIAL | 100788875 |
| 20215076 | 20088704 | 1.82 | 81.9 | null | 2017-07-23 | 2017-08-07 | MPT | 02 | Y | GEMCITABINE + PACLITAXEL | 100048467 |
| 20215121 | 20088705 | 0 | 0 | Palliative (P) | 2017-09-07 | 2017-10-04 | EEF or EOF | N | N | RITUXIMAB | 100546650 |
| 20215258 | 20088706 | 1.83 | null | Palliative (P) | 2018-08-19 | 2018-08-19 | Bortezomib + Panobinostat | N | null | NOT MATCHED | 100417018 |
| 20215259 | 20088707 | 1.54 | 67.1 | Palliative (P) | 2017-12-07 | 2018-02-09 | NIVOLUMAB | 02 | Y | DOCETAXEL | 100088862 |
| 20215305 | 20088708 | null | 11.2 | Adjuvant (A) | 2019-02-08 | 2019-02-11 | Cetuximab + Radiotherapy Maint | 02 | Y | DARATUMUMAB | 101694657 |
| 20215493 | 20088710 | 1.6 | 63 | 03 | 2019-05-08 | 2019-05-08 | CISPLATIN + FLUOROURACIL + RT | Y | N | NIVOLUMAB | 101329471 |
| 20215650 | 20088711 | 1.75 | 57 | 03 | 2019-05-26 | 2019-06-08 | NIVOLUMAB | 02 | N | GEMCITABINE + PACLITAXEL | 100892795 |
| 20215671 | 20088712 | 1.71 | 91.65 | Palliative (P) | 2017-04-24 | 2017-05-02 | null | N | N | STREPTOZOCIN | 101362840 |
| 20215711 | 20088713 | 1.67 | 46.5 | Palliative (P) | 2017-09-15 | 2017-09-15 | null | 02 | N | CAPECITABINE + CETUXIMAB + IRINOTECAN | 100941250 |
| 20215764 | 20088716 | 1.56 | 71.8 | Palliative (P) | null | 2017-08-18 | Docetaxel | 01 | N | CYCLOPHOSPHAMIDE + RITUXIMAB | 100878891 |
| 20215799 | 20088717 | 1.63 | 73.7 | 03 | 2017-05-11 | 2017-06-07 | Paclitaxel 80mg/m2 day 1 8 15 | 01 | N | CARBOPLATIN + PEMETREXED | 101218620 |